Mediterranean diet and physical activity decrease the initiation of cardiovascular drug use in high cardiovascular risk individuals: A cohort study
Autor/a
Otros/as autores/as
Fecha de publicación
2021-03Resumen
Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose-lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin (HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56–0.84]). LTPA was non-linearly related to a delayed initiation of glucose-lowering, antihypertensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180–360 metabolic equivalents of task-min/day). Both combined were synergistically associated with a decreased onset of glucose-lowering drugs (p-interaction = 0.04), antihypertensive drugs (p-interaction < 0.001), vitamin K antagonists (p-interaction = 0.04), and cardiac glycosides (p-interaction = 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk of initiating cardiovascular-related medications.
Tipo de documento
Artículo
Versión del documento
Versión publicada
Lengua
Inglés
Palabras clave
Dieta mediterrània
Exercici
Medicaments
Glucosa
Antihipertensius
Estatines (Medicaments cardiovasculars)
Fibrats
Antiagregants
Vitamines K -- Inhibidors
Antianginosos
Glucòsids cardíacs
Páginas
14 p.
Publicado por
MDPI
Publicado en
Antioxidants, 2021, 10(3): 397
Número del acuerdo de la subvención
info:eu-repo/grantAgreement/MINECO/ISCIII/OBN17PI02
info:eu-repo/grantAgreement/MINECO/ISCIII/CB06/03/0019
info:eu-repo/grantAgreement/MINECO/ISCIII/CB06/03/0028
info:eu-repo/grantAgreement/MINECO/ISCIII/CD17/00122
info:eu-repo/grantAgreement/SUR del DEC/SGR/2017BP00021
info:eu-repo/grantAgreement/SUR del DEC/SGR/2017SGR222
info:eu-repo/grantAgreement/MEFPU/FPU/FPU17/00785
Este ítem aparece en la(s) siguiente(s) colección(ones)
Derechos
© L'autor/a
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by/4.0/